Drug profile · INN
benoxinate hydrochloride
ALTAFLUOR BENOX
benoxinate hydrochloride (ALTAFLUOR BENOX) is a sodium channel alpha subunit blocker. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — benoxinate hydrochloride
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
benoxinate hydrochloride (ALTAFLUOR BENOX) is a sodium channel alpha subunit blocker. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel alpha subunit blocker
Primary target: Sodium channel alpha subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is benoxinate hydrochloride?
benoxinate hydrochloride (ALTAFLUOR BENOX) is a sodium channel alpha subunit blocker. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for benoxinate hydrochloride?
ALTAFLUOR BENOX is a marketed brand name for benoxinate hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of benoxinate hydrochloride?
benoxinate hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.